[Vaccine from soluble antigens for the specific therapy of Proteus infection].
A vaccine prepared from Proteus soluble antigens obtained by the disintegration of microbial cells with hydroxylamine is proposed. In animal experiments the vaccine has proved to be nontoxic when injected in large single doses or in smaller doses over a prolonged period and capable of protecting mice and rabbits from Proteus infection. No pronounced postvaccinal complications have been registered in humans immunized with the vaccine. The possibility of using the vaccine for immunizing donors with the aim of obtaining hyperimmune anti-Proteus plasma and for the active vaccinal therapy of patients with Proteus infection has been shown.
D000818:Animals; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000276:immunology / Q000302:isolation & purification*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000302:isolation & purification* / Q000627:therapeutic use; D004306:Dose-Response Relationship, Immunologic; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006168:Guinea Pigs; D006801:Humans; D007114:Immunization; D051379:Mice; D011511:Proteus / Q000276:immunology*; D011512:Proteus Infections / Q000276:immunology / Q000628:therapy*; D011817:Rabbits; D012995:Solubility; D013997:Time Factors
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines
Vaktsina iz rastvorimykh abtigenov dlia spetsificheskoĭ terapii proteĭnoĭ infektsii.